• Recruiting

NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

Updated: Oct 23

STOMP


Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

stomp study selinexor xkd

STOMP

This study will independently assess the efficacy and safety of 10 combination therapies in 11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM).


Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)


Sponsor

Karyopharm Therapeutics Inc

 

ClinicalTrials.gov Identifier: NCT02343042

Official Title: A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

First Posted : January 21, 2015

Click here for details on ClinicalTrials.gov

 

Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information

 

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Blood. 2018 Dec 13

Click here for details

 

1651 Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Program: Oral and Poster Abstracts

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I

Hematology Disease Topics & Pathways:

Clinical Trials, Acute Myeloid Malignancies, Adults, Clinical Research, Study Population

Saturday, December 11, 2021, 5:30 PM-7:30 PM

Click here for details

 

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Br J Cancer. 2022 Mar 23

Click here for details

 

Drug: Selinexor

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Pomalidomide

Drug: Bortezomib

Drug: Daratumumab

Drug: Carfilzomib

Drug: Ixazomib

Drug: Elotuzumab

Drug: Clarithromycin

Drug: Belantamab Mafodotin

 

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- New Jersey: Hackensack University Medical Center

- New York: Columbia University Medical Center New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- New York: University of Rochester New York

- Nebraska: University of Nebraska Medical Center Omaha

- Tennessee: Sarah Cannon Research Institute Nashville

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Massachusetts

United States, Nebraska

United States, New Jersey

United States, New York

United States, North Carolina

United States, Tennessee

United States, Washington

United States, Wisconsin

Canada, Alberta

Canada, British Columbia

Canada, Manitoba

Canada, Newfoundland and Labrador

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec



Posts Archive